Certain patients who have aortic stenosis cannot survive a surgical procedure. We make innovative medical devices that can address this multi-billion market.
At Syntheon Cardiology, our goal is to bring to market the next generation of Transcatheter Aortic Valve Replacement (TAVR) device. The current devices have clinical issues. are difficult to use, and do not have feedback for the physician. Our device is the only microprocessor-controlled device which enables the physician to know the force and diameter of the aortic implant and provides unparalleled control over the procedure.